Alpha 2.0
Login Register
» Authors » Murdo Ferguson

Murdo Ferguson

Explore the profile of Murdo Ferguson including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 18
Citations 308
Followers 0
Related Specialties
Allergy & Immunology
Infectious Diseases
Pulmonary Medicine
Top 10 Co-Authors
Paul Rheault
Anne Schuind
Tino F Schwarz
Marc Dionne
Ping Li
Jyoti Soni
Anuradha Madan
Frank Struyf
Bruce L Innis
Damien Friel
Published In
Vaccine
J Infect Dis
Hum Vaccin Immunother
Clin Infect Dis
Lancet Infect Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
Noninferior Immunogenicity and Consistent Safety of Respiratory Syncytial Virus Prefusion F Protein Vaccine in Adults 50-59 Years Compared to ≥60 Years of Age
Ferguson M, Schwarz T, Nunez S, Rodriguez-Garcia J, Mital M, Zala C, et al.
Clin Infect Dis . 2024 Aug; 79(4):1074-1084. PMID: 39099093
Background: The adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine (RSVPreF3 OA) is approved in adults aged ≥60 years. We evaluated RSVPreF3 OA immunogenicity and safety in adults aged...
2.
Lot-to-lot immunogenicity consistency of the respiratory syncytial virus prefusion F protein vaccine in older adults
Ferguson M, Murray A, Pliamm L, Rombo L, Berglund J, David M, et al.
Vaccine X . 2024 May; 18:100494. PMID: 38746060
Background: Previous phase 3 studies showed that the AS01-adjuvanted respiratory syncytial virus (RSV) prefusion F protein-based vaccine for older adults (RSVPreF3 OA) is well tolerated and efficacious in preventing RSV-associated...
3.
Safety and Immunogenicity of Respiratory Syncytial Virus Prefusion Maternal Vaccine Coadministered With Diphtheria-Tetanus-Pertussis Vaccine: A Phase 2 Study
Hermida N, Ferguson M, Leroux-Roels I, Pagnussat S, Yaplee D, Hua N, et al.
J Infect Dis . 2023 Dec; 230(2):e353-e362. PMID: 38133639
Background: Respiratory syncytial virus (RSV) fusion protein stabilized in the prefusion conformation (RSVPreF3) was under investigation as a maternal vaccine. Methods: This phase 2, randomized, placebo-controlled, single-dose, multicenter study enrolled...
4.
Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study
Galgani I, Annaratone M, Casula D, Di Maro G, Janssens M, Tasciotti A, et al.
Respir Res . 2022 May; 23(1):114. PMID: 35509077
Background: Non-typeable Haemophilus influenzae (NTHi) and Moraxella catarrhalis (Mcat) infections are frequently associated with exacerbations of chronic obstructive pulmonary disease (COPD). Results were reported with a two-dose (0-2 months) schedule...
5.
A new fully liquid presentation of MenACWY-CRM conjugate vaccine: Results from a multicentre, randomised, controlled, observer-blind study
Vandermeulen C, Leroux-Roels I, Vandeleur J, Staniscia T, Girard G, Ferguson M, et al.
Vaccine . 2021 Oct; 39(45):6628-6636. PMID: 34635373
Background: The currently licensed quadrivalent MenACWY-CRM conjugate vaccine presentation consists of two vials (lyophilised MenA and liquid MenCWY) to be reconstituted before injection. A new fully liquid formulation in a...
6.
The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70
Boutry C, Hastie A, Diez-Domingo J, Tinoco J, Yu C, Andrews C, et al.
Clin Infect Dis . 2021 Jul; 74(8):1459-1467. PMID: 34283213
Background: This ongoing follow-up study evaluated the persistence of efficacy and immune responses for 6 additional years in adults vaccinated with the glycoprotein E (gE)-based adjuvanted recombinant zoster vaccine (RZV)...
7.
Long-term Cross-reactivity Against Nonvaccine Human Papillomavirus Types 31 and 45 After 2- or 3-Dose Schedules of the AS04-Adjuvanted Human HPV-16/18 Vaccine
Folschweiller N, Behre U, Dionne M, Durando P, Esposito S, Ferguson L, et al.
J Infect Dis . 2019 Feb; 219(11):1799-1803. PMID: 30715452
This analysis focused on long-term cross-reactive immunogenicity against nonvaccine human papillomavirus (HPV) types 31 and 45 following 2 doses of AS04-adjuvanted HPV-16/18 vaccine in girls aged 9-14 years or following...
8.
Corrigendum to 'Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial' [Vaccine 36 (2018) 4278-4286]
Marechal C, Lal H, Poder A, Ferguson M, Enweonye I, Heineman T, et al.
Vaccine . 2019 Feb; 37(9):1252-1253. PMID: 30711316
No abstract available.
9.
Antibody persistence and booster response in adolescents and young adults 4 and 7.5 years after immunization with 4CMenB vaccine
Nolan T, Santolaya M, De Looze F, Marshall H, Richmond P, Henein S, et al.
Vaccine . 2019 Jan; 37(9):1209-1218. PMID: 30691980
Background: Data on duration of protection against invasive meningococcal disease post-vaccination with the recombinant, 4-component, meningococcal serogroup B vaccine (4CMenB) are limited. We evaluated bactericidal activity persistence in adolescents/young adults...
10.
Immunogenicity and safety of the adjuvanted recombinant zoster vaccine co-administered with the 23-valent pneumococcal polysaccharide vaccine in adults ≥50 years of age: A randomized trial
Marechal C, Lal H, Poder A, Ferguson M, Enweonye I, Heineman T, et al.
Vaccine . 2018 Jun; 36(29):4278-4286. PMID: 29903674
Background: This study evaluated immunogenicity and safety of the adjuvanted recombinant zoster vaccine (RZV) when the first dose was co-administered with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults aged...